US2008227850A1PendingUtilityA1

Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms

Assignee: WYETH CORPPriority: Oct 15, 2002Filed: Jan 21, 2008Published: Sep 18, 2008

Est. expiryOct 15, 2022(expired)· nominal 20-yr term from priority

Inventors:Darlene Coleman Deecher Istvan Jozsef Merchenthaler Liza Leventhal Kimberly Jean Sipe Lawrence T. O'Connor

A61P 5/00A61P 9/00A61P 43/00A61P 25/00A61P 25/20A61K 31/55A61K 31/497A61K 31/155A61P 15/12A61K 31/5377A61K 31/138A61K 31/496A61K 31/4174A61K 31/167A61K 31/137A61K 31/13A61K 31/381

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.

Claims

exact text as granted — not AI-modified

1 . A method for treating or preventing vasomotor symptoms in a subject in need thereof, comprising the step of: administering to said subject a therapeutically effective amount of at least one dual NRI/SRI compound or pharmaceutically acceptable salt thereof, wherein said amount is less than about 37.5 mg/day. 
     
     
         2 . A method according to  claim 1 , wherein said amount is less than about 30 mg/day. 
     
     
         3 . A method according to  claim 1 , wherein said amount is less than about 25 mg/day. 
     
     
         4 . A method according to  claim 1 , wherein said amount is less than about 20 mg/day. 
     
     
         5 . A method according to  claim 1 , wherein said amount is less than about 15 mg/day. 
     
     
         6 . A method according to  claim 1 , wherein said amount is less than about 10 mg/day. 
     
     
         7 . A method according to  claim 1 , wherein said amount is less than about 5 mg/day. 
     
     
         8 . A method according to  claim 1 , wherein said dual NRI/SRI compound is a compound selected from the group consisting of venlafaxine, O-desmethyl-venlafaxine, duloxetine, and combinations and pharmaceutically acceptable salts thereof. 
     
     
         9 . A method according to  claim 1 , wherein said dual NRI/SRI compound is venlafaxine or a pharmaceutically acceptable salt thereof. 
     
     
         10 . A method according to  claim 1 , wherein said dual NRI/SRI compound is O-desmethyl-venlafaxine or a pharmaceutically acceptable salt thereof. 
     
     
         11 . A method according to  claim 1 , wherein said dual NRI/SRI compound is duloxetine or a pharmaceutically acceptable salt thereof. 
     
     
         12 . A method according to  claim 1 , wherein said vasomotor symptom is hot flush. 
     
     
         13 . A method according to  claim 1 , wherein said vasomotor symptom is caused by a thermoregulatory dysfunction. 
     
     
         14 . A method according to  claim 1 , wherein said subject is human. 
     
     
         15 . A method according to  claim 14 , wherein said human is a female. 
     
     
         16 . A method according to  claim 15 , wherein said female is pre-menopausal. 
     
     
         17 . A method according to  claim 15 , wherein said female is peri-menopausal. 
     
     
         18 . A method according to  claim 15 , wherein said female is post-menopausal. 
     
     
         19 . A method according to  claim 14 , wherein said human is a male. 
     
     
         20 . A method according to  claim 19 , wherein said male is naturally, chemically or surgically andropausal.

Join the waitlist — get patent alerts

Track US2008227850A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.